丽珠医药注射用JP-1366完成II期临床试验首例患者给药

港美通
Oct 31, 2025

10月31日,据丽珠医药公众号,丽珠医药研发的注射用 JP-1366(英文名:Zastaprazan citrate for Injection)已于近日顺利完成 Ⅱ 期临床试验首例患者给药。目前中国尚无 P-CAB 针剂获批上市,该药物有望为消化性溃疡出血患者提供全新的临床用药方案。据介绍,溃疡性出血是最严重的消化道溃疡并发症之一,可能导致患者休克,甚至危及生命,是我国常见的临床急症。患者一旦...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10